The most common side effects reported in clinical trials were nausea, vomiting, diarrhea, constipation, and reduced appetite
And in 2023, it approved the GLP-1 Zepbound
Leucaena leucocephala is native to Northern Central America and Southern Mexico (336, 337)
This makes it a promising therapy for digestive disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and leaky gut syndrome (intestinal permeability)
As of March 2024 , Wegovys labeling was updated and no longer includes specific BMI criteria
Overview of efficacy, side effects, and key challenges GLP-1 receptor agonists such as semaglutide and liraglutide, as well as combination agents like tirzepatide (which adds glucose-dependent insulinotropic polypeptide receptor agonism)all hereafter referred to as GLP-1s for brevityare effective new agents for obesity treatment which demonstrate weight reduction, weight maintenance, and reduced morbidity and mortality